- Long-term OS with durvalumab after chemoradiotherapy (CRT) for stage III unresectable NSCLC was significantly better than with placebo, with nearly 60% of patients alive at 3 years posttreatment.
Why this matters
- Initial results from phase 3 PACIFIC trial led to the approval of durvalumab for the treatment of unresectable stage III NSCLC without progression on CRT.
- Long-term outcomes from the randomized, phase 3 PACIFIC trial.
- 709 patients with stage III unresectable NSCLC and no progression after CRT received durvalumab (n=473) or placebo (n=236).
- Median follow-up, 33.3 months.
- Funding: AstraZeneca.
- Durvalumab was associated with a significant decrease in mortality risk (HR, 0.69; 95% CI, 0.55-0.86).
- Better OS with durvalumab vs placebo at 12 months (83.1% vs 74.6%), 24 months (66.3% vs 55.3%), and 36 months (57.0% vs 43.5%).
- Durvalumab was associated with longer time to first subsequent therapy or death (HR, 0.58; 95% CI, 0.47-0.71) and time to second subsequent therapy or death (HR, 0.61; 95% CI, 0.49-0.75).
- Programmed death-ligand 1 expression not available in some patients.